342 Chapter 12 Supplementary Figure 6 Supplementary Figure 6. Optimization of AAV.I-1c dosage in the D4iR14del line. (A) qPCR analysis of Inhibitor 1 (I-1c) expression after different MOI concentrations of AAV.I-1c treatment. * P < 0.05 vs. untreated control (CTRL) by one-way ANOVA. Each dot represents a sample of 20 spheroids and 1-2 biological replicates per condition were included in this analysis. (B) Functional beating viability of hCSs after different MOI concentrations of AAV.I-1c treatment. Each dot represents the percentage of beating hCSs per experiment. N=2 per condition. (C) Measurement of Ca2+ handling parameters from automated recorded data (D) Comparison of decay time (Tau), Ca2+ transient amplitude, and beating rate after different MOI concentrations of AAV.I-1c treatment. * P< 0.05 - **** P < 0.0001 vs. each group by one-way ANOVA. Each dot represents one individual spheroid, n=48-24 spheroids, and 2 biological replicates per condition were included in this analysis.
RkJQdWJsaXNoZXIy MTk4NDMw